TCBP vs. SCNI, SQZ, ACORQ, WINT, ELOX, ALBT, GMDAQ, EVFM, SPRC, and SDCCQ
Should you be buying TC Biopharm stock or one of its competitors? The main competitors of TC Biopharm include Scinai Immunotherapeutics (SCNI), SQZ Biotechnologies (SQZ), Acorda Therapeutics (ACORQ), Windtree Therapeutics (WINT), Eloxx Pharmaceuticals (ELOX), Avalon GloboCare (ALBT), Gamida Cell (GMDAQ), Evofem Biosciences (EVFM), SciSparc (SPRC), and SmileDirectClub (SDCCQ). These companies are all part of the "medical" sector.
Scinai Immunotherapeutics (NASDAQ:SCNI) and TC Biopharm (NASDAQ:TCBP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.
TC Biopharm received 1 more outperform votes than Scinai Immunotherapeutics when rated by MarketBeat users.
58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 16.3% of TC Biopharm shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 0.1% of TC Biopharm shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Scinai Immunotherapeutics and Scinai Immunotherapeutics both had 2 articles in the media. Scinai Immunotherapeutics' average media sentiment score of 0.54 beat TC Biopharm's score of 0.16 indicating that TC Biopharm is being referred to more favorably in the news media.
Scinai Immunotherapeutics has a beta of 2.45, indicating that its share price is 145% more volatile than the S&P 500. Comparatively, TC Biopharm has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500.
Scinai Immunotherapeutics has higher earnings, but lower revenue than TC Biopharm.
Summary
Scinai Immunotherapeutics and TC Biopharm tied by winning 4 of the 8 factors compared between the two stocks.
Get TC Biopharm News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TC Biopharm Competitors List
Related Companies and Tools
